cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Iveric Bio Inc
4 own
10 watching
Current Price
$23.24
$-0.75
(-3.13%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,802.11M
52-Week High
52-Week High
24.56
52-Week Low
52-Week Low
8.85
Average Volume
Average Volume
1.68M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization2,802.11M
icon52-Week High24.56
icon52-Week Low8.85
iconAverage Volume1.68M
iconDividend Yield--
iconP/E Ratio--
What does the Iveric Bio Inc do?
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.
Read More
How much money does Iveric Bio Inc make?
News & Events about Iveric Bio Inc.
Business Wire
1month ago
IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on January 3, 2023, the Company granted equity-based awards pursuant to the Companys 2019 Inducement Stock Incentive Plan to twelve newly-hired, non-executive employees. These inducement grants were approved by the Companys compensation and talent...
Business Wire
1month ago
IVERIC bio, Inc. (Nasdaq: ISEE) announced today the election of Pravin U. Dugel, MD, President of Iveric Bio, to its Board of Directors, effective as of January 1, 2023. Dr. Dugel has been instrumental in helping to shape the Companys business strategy and in overseeing the development and...
Business Wire
1month ago
IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the third and final part of its New Drug Application (NDA) for rolling review of avacincaptad pegol (ACP), a novel investigational complement C5 inhibitor for the treatment of...
Business Wire
2 months ago
IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on December 1, 2022, the Company granted equity-based awards pursuant to the Companys 2019 Inducement Stock Incentive Plan to nine newly-hired, non-executive employees. These inducement grants were approved by the Companys compensation and talent...
Business Wire
2 months ago
IVERIC bio, Inc. (Nasdaq: ISEE) (the Company), today announced the pricing of an upsized underwritten public offering of 13,350,000 shares of its common stock at a price to the public of $22.50 per share, less underwriting discounts and commissions. In addition, in connection with the offering, the...
Frequently Asked Questions
Frequently Asked Questions
What is Iveric Bio Inc share price today?
plus_minus_icon
Can Indians buy Iveric Bio Inc shares?
plus_minus_icon
How can I buy Iveric Bio Inc shares from India?
plus_minus_icon
Can Fractional shares of Iveric Bio Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Iveric Bio Inc stocks?
plus_minus_icon
What is today’s traded volume of Iveric Bio Inc?
plus_minus_icon
What is today’s market capitalisation of Iveric Bio Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Iveric Bio Inc?
plus_minus_icon
What percentage is Iveric Bio Inc down from its 52-Week High?
plus_minus_icon
What percentage is Iveric Bio Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$23.24
$-0.75
(-3.13%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00